Literature DB >> 12362256

Imiquimod: a review.

Aditya K Gupta1, Melanie Browne, Robyn Bluhm.   

Abstract

BACKGROUND AND
OBJECTIVE: Imiquimod (Aldara) is an immune response modifier used primarily to treat anogenital warts. Imiquimod induces cytokines and enhances cell-mediated cytolytic antiviral activity in vivo. It exhibits antiviral and antitumor effects; however, it does not exhibit direct antiviral effects in vitro. By inducing cytokines, such as interferon a, imiquimod stimulates both the innate immune response and the cellular arm of acquired immunity. Currently, imiquimod is approved for use in the treatment of external genital and perianal warts in adults.
CONCLUSION: Beyond its established use, there are case reports and preliminary studies suggesting the effectiveness of imiquimod 5% cream in the treatment of nongenital human papillomavirus warts, molluscum contagiosum, actinic keratosis, basal cell carcinoma, squamous cell carcinoma, Bowen's disease, nongenital human papillomavirus infection, and vulvar intraepithelial neoplasia.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12362256     DOI: 10.1007/s10227-001-0134-6

Source DB:  PubMed          Journal:  J Cutan Med Surg        ISSN: 1203-4754            Impact factor:   2.092


  8 in total

1.  Malignancies of the anal margin and perianal skin.

Authors:  E Dawn Wietfeldt; James Thiele
Journal:  Clin Colon Rectal Surg       Date:  2009-05

2.  Toll-like receptor-7 ligand Imiquimod induces type I interferon and antimicrobial peptides to ameliorate dextran sodium sulfate-induced acute colitis.

Authors:  Satheesh K Sainathan; Kumar S Bishnupuri; Konrad Aden; Qizhi Luo; Courtney W Houchen; Shrikant Anant; Brian K Dieckgraefe
Journal:  Inflamm Bowel Dis       Date:  2011-09-26       Impact factor: 5.325

3.  IL-1 signalling determines the fate of skin grafts expressing non-self protein in keratinocytes.

Authors:  Usriansyah Hadis; Graham R Leggatt; Ranjeny Thomas; Ian H Frazer; Eva M Kovacs
Journal:  Exp Dermatol       Date:  2010-08       Impact factor: 3.960

4.  Long-term functional and quality of life outcomes of patients after repair of large perianal skin defects for Paget's and Bowen's disease.

Authors:  Alissa Conklin; Imran Hassan; Heidi K Chua; E Dawn Wietfeldt; Dirk R Larson; Kristine A Thomsen; Sanhat Nivatvongs
Journal:  J Gastrointest Surg       Date:  2009-02-18       Impact factor: 3.452

5.  Topical Formulation of Noscapine, a Benzylisoquinoline Alkaloid, Ameliorates Imiquimod-Induced Psoriasis-Like Skin Lesions.

Authors:  Fahimeh Nourbakhsh; Seyed Hadi Mousavi; Pouria Rahmanian-Devin; Vafa Baradaran Rahimi; Hassan Rakhshandeh; Vahid Reza Askari
Journal:  Evid Based Complement Alternat Med       Date:  2022-04-22       Impact factor: 2.650

6.  Discovering Common Pathophysiological Processes between COVID-19 and Cystic Fibrosis by Differential Gene Expression Pattern Analysis.

Authors:  Md Tanvir Hasan; Lway Faisal Abdulrazak; Mohammad Khursheed Alam; Md Rezwan Islam; Yeasmin Hena Sathi; Fahad Ahmed Al-Zahrani; Kawsar Ahmed; Francis M Bui; Mohammad Ali Moni
Journal:  Biomed Res Int       Date:  2022-04-29       Impact factor: 3.246

7.  Imiquimod does not affect shedding of viable chlamydiae in a murine model of Chlamydia trachomatis genital tract infection.

Authors:  Kyle H Ramsey; Namir Shaba; Kevin P Cohoon; Kevin A Ault
Journal:  Infect Dis Obstet Gynecol       Date:  2003

8.  Imiquimod - A toll like receptor 7 agonist - Is an ideal option for management of COVID 19.

Authors:  Athina Angelopoulou; Nikos Alexandris; Evangelia Konstantinou; Konstantinos Mesiakaris; Charilaos Zanidis; Konstantinos Farsalinos; Konstantinos Poulas
Journal:  Environ Res       Date:  2020-06-23       Impact factor: 6.498

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.